目的 基于 CiteSpace 6.2.R6 對(duì)“中藥治療高尿酸血癥腎病”的中文及英文文獻(xiàn)進(jìn)行文獻(xiàn)計(jì)量學(xué)及可視化分析，探討中藥治療高尿酸血癥腎病的研究現(xiàn)狀及趨勢(shì)，為將來(lái)的基礎(chǔ)研究和臨床研究提供參考。方法 以中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)（CNKI）、萬(wàn)方數(shù)據(jù)知識(shí)服務(wù)平臺(tái)（Wanfang）、維普中文科技期刊數(shù)據(jù)庫(kù)（VIP）作為中藥治療高尿酸血癥腎病的中文文獻(xiàn)的檢索平臺(tái)，英文文獻(xiàn)以 Web of Science（WOS）為檢索平臺(tái)，不限制文獻(xiàn)發(fā)表時(shí)間。應(yīng)用 CiteSpace 6.2.R6 版軟件對(duì)文獻(xiàn)作者和機(jī)構(gòu)進(jìn)行合作分析，對(duì)關(guān)鍵詞進(jìn)行共現(xiàn)分析，以此提取可靠信息。結(jié)果 通過(guò)檢索共得到 395 篇中文和 48 篇英文文獻(xiàn)，可視化分析結(jié)果顯示中英文文獻(xiàn)發(fā)文量整體呈上升趨勢(shì)，但是年均發(fā)文量表明中藥治療高尿酸血癥腎病的研究并不多。作者合作網(wǎng)絡(luò)分析顯示作者之間存在交流合作，但是較為分散，合作不夠密切，該領(lǐng)域主要由國(guó)內(nèi)學(xué)者進(jìn)行研究，機(jī)構(gòu)間合作相對(duì)獨(dú)立，主要單位為國(guó)內(nèi)中醫(yī)藥大學(xué)及其當(dāng)?shù)蒯t(yī)院，缺乏跨省交流，更沒(méi)有跨國(guó)合作。關(guān)鍵詞共現(xiàn)分析表明高尿酸血癥腎病的直接作用器官為腎臟，中藥同高尿酸血癥腎病聯(lián)系比較密切，提示了中藥治療高尿酸血癥腎病的更多方向和可能。中文關(guān)鍵詞聚類分析表明該項(xiàng)研究多集中于臨床層次，缺乏基礎(chǔ)性研究。英文關(guān)鍵詞聚類展示了與中藥治療高尿酸血癥腎病相關(guān)性比較大的兩種分子，分別是白細(xì)胞介素-1（IL-1）和核苷酸結(jié)合寡聚化結(jié)構(gòu)域樣受體含 pyrin 結(jié)構(gòu)域蛋白3（NLRP3）。分析總結(jié)出該研究未來(lái)趨勢(shì)更趨向于先應(yīng)用生物醫(yī)藥大數(shù)據(jù)來(lái)探尋中藥同高尿酸血癥腎病的相關(guān)聯(lián)系，在此基礎(chǔ)上進(jìn)行深入研究，這也反映該項(xiàng)研究正處于發(fā)展階段。結(jié)論 中藥已經(jīng)應(yīng)用于高尿酸血癥腎病的臨床治療中，對(duì)疾病起著一定作用，但是缺乏對(duì)其深入的基礎(chǔ)性研究，因此限制了臨床研究的發(fā)展。

Objective Based on CiteSpace 6.2. R6, to conducte bibliometric and visualization analyses of Chinese and English literature on traditional Chinese medicine for hyperuricemia nephropathy to understand the current status and trend of research on the treatment of hyperuricemia nephropathy by traditional Chinese medicine, and to provide references for future basic research and clinical research. Methods China Knowledge Network Database (CNKI), Wanfang Data Knowledge Service Platform (Wanfang), and Vip. com (VIP) were used as the search platforms for the Chinese literature on Chinese medicines for hyperuricemia nephropathy, and Web of science (WOS) was used as the search platform for the English literature, with no restriction on the publication time of the literature. And CiteSpace version 6.2. R6 software was applied to analyze the collaboration of literature authors and institutions, and to analyze the co-occurrence of keywords as a way to extract reliable information. Results A total of 395 Chinese and 48 English documents were obtained through the search, and the results of the visualization analysis showed that the number of Chinese and English literature publications showed an overall increasing trend, but the average annual number of publications indicated that there were not many studies on the treatment of hyperuricemia nephropathy with traditional Chinese medicine. The analysis of authors' cooperation network showed that there was communication and cooperation among authors, but it was more scattered and the cooperation was not close enough. This field was mainly researched by domestic authors, and the interinstitutional cooperation was relatively independent, with the main units being the domestic universities of traditional Chinese medicine and their local hospitals, and there was a lack of inter-provincial communication, not to mention transnational cooperation. Keyword co-occurrence analysis indicated that the direct organ of action of hyperuricemia nephropathy was the kidney, and that traditional Chinese medicine was more closely associated with hyperuricemia nephropathy, suggesting more directions and possibilities for the treatment of hyperuricemia nephropathy with traditional Chinese medicine. The keyword clustering analysis in Chinese showed that the study was mostly focused on the clinical level and lacked basic research. The keyword clustering analysis in English showed two molecules that were more relevant to the treatment of hyperuricemia nephropathy with traditional Chinese medicine, which were interleukin-1 (IL-1) and NLRP3. The analysis summarized that the future trend of this study was to apply the big data of biomedicine to explore the connection between traditional Chinese medicine and hyperuricemia nephropathy, and then carried out in-depth research on the basis of it, which was also a reflection of the developmental stage of this study. This also indicated that the study was in the development stage. Conclusion Traditional Chinese medicine has been used in clinical research on hyperuricemia nephropathy and plays a role in the disease, but lacks in-depth basic research, thus limiting the development of clinical research.

國(guó)家自然科學(xué)基金面上項(xiàng)目（82301725）；中國(guó)博士后科學(xué)基金第 73 批面上資助項(xiàng)目（2023M732155）；山西省基礎(chǔ)研究計(jì)劃面上 項(xiàng) 目（202203021212028）；山 西 省 高 等 學(xué) 校 科 技 創(chuàng) 新 項(xiàng) 目（2022L132）；山 西 省 衛(wèi) 生 健 康 委 中 醫(yī) 藥 科 研 項(xiàng)目（2023ZYYC2034）；山西省科技廳基礎(chǔ)研究項(xiàng)目（20210302124586）；山西省應(yīng)用基礎(chǔ)研究計(jì)劃（201901D211573）；太原市科技局“雙百攻關(guān)行動(dòng)”首批關(guān)鍵核心技術(shù)攻關(guān)“揭榜掛帥”項(xiàng)目（2024TYJB0150）